GU Cancers 2019 | IO-IO vs. IO-VEGF inhibitor therapy for mRCC

Shaan Dudani

Combinations of immuno-oncology (IO) agents with other IO agents, or vascular endothelial growth factor (VEGF) inhibitors, have shown promises as first-line treatments for metastatic renal cell carcinoma (mRCC). However, the comparative efficacy of these combinations against each other has not yet been investigated. Shaan Dudani, MBChB, of the Tom Baker Cancer Centre, Alberta, Canada, reports that a study has been carried to compare the outcomes in mRCC patients treated with IO-IO combinations, versus those treated with IO-VEFG inhibitor combinations, using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) dataset. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco.

Share this video